Novartis’ “Living Drugs”: Kymriah, Zolgensma – And Diovan?
Executive Summary
Novartis is pioneering the new “living drugs” model. But its present financial performance benefits from regulatory problems that have beset generic competitors to a franchise written off for dead: the antihypertensive brand Diovan (valsartan).
You may also be interested in...
Novartis CEO Calms Concerns Over Zolgensma launch
The Swiss major has posted a strong set of financials for the second quarter and Vas Narasimhan is pleased with the roll-out of Zolgensma, Mayzent and Piqray.
House Committee Wants Answers On Foreign Inspections And Valsartan Crisis
A bipartisan group of lawmakers is concerned about the growing number of recalls of blood pressure medicines from foreign manufacturing sites in China and India and wants answers from GAO and FDA.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.